For information on this past event please contact Meetings Management

Second Circular and Provisional Conference Programme

The 1st International Conference on

Malaria Vaccines for the World
17-19 September 2007, Royal Society of Medicine, London, UK

More than a third of the world’s population is at risk of contracting malaria – it is estimated that 200 people, primarily children in Africa, die of malaria every hour of every day every year. Malaria is one of the main obstacles to socio-economic development in Africa. Effective vaccines against malaria would have an enormous effect on reducing the negative impact of malaria.

This new conference – MALARIA VACCINES FOR THE WORLD – MVW 2007 will offer researchers a fresh new forum to discuss the current status of new malaria vaccines initiatives, vaccine candidates and clinical trials. MVW 2007 will focus attention on ‘Vaccine Issues’ in relation to Malaria as a worldwide disease.

MVW 2007 will be of interest to scientists, physicians and other professionals from the academic, industrial/commercial and governmental/policy/regulatory sectors who have an interest in the development, assessment, trends and deployment of vaccines for the worldwide problem that is malaria – the cause of over two million deaths worldwide each year.

Scientific Advisory Panel

Stephen L. Hoffman (Sanaria Inc., Maryland, USA)
Adrian Hill (University of Oxford, UK)
Denise Doolan (Naval Medical Research Center, Maryland, USA)
Eleanor Riley (London School of Hygiene & Tropical Medicine, UK)
Michael Good (Queensland Institute of Medical Research, Brisbane, Australia)
Joe Cohen (GlaxoSmithKline Biologicals, Rixensart, Belgium)
Jean Langhorne (NIMR, Mill Hill, London, UK)
Graham V. Brown (University of Melbourne, Australia)
David E. Lanar (WRAIR, Maryland, USA)
Ross L. Coppel (Monash University, Victoria, Australia)
David E. Arnot (University of Edinburgh, UK)
Carole Long (NIH/NIAID, Maryland, USA)
Blaise Genton (Ifakara Research & Development Centre, Dar es Salaam, Tanzania)
Ruth S. Nussenzweig (New York University, USA)
Odile Leroy (EDCTP, Denmark)
Christian Loucq (PATH Malaria Vaccine Initiative, Bethesda, Maryland, USA)

Conference Scope and Sessions

The MVW 2007 scientific programme includes keynote lectures, contributed papers and poster presentations emphasising all aspects of Malaria Vaccines as outlined below.

The MVW 2007 conference will focus on the following main session topics:

• Epidemiology: The overall malaria problem with emphasis on the epidemiology of uncomplicated, severe and fatal malaria in infants, children and pregnant woman in different geographic and transmission regions, and in high and low risk population groups.
• Immunology: The immunology that supports malaria vaccine development including the delineation of protective immune responses through study of immunoepidemiology, model systems, and vaccine-immunized volunteers.
• Target Discovery: The known pre-erythrocytic, asexual erythrocytic, and sexual erythrocytic antigen targets for vaccine development, and efforts to discover new targets using genomics-based and other strategies.
• Immunogen Construction: Status of work on recombinant protein, synthetic peptide, recombinant virus, recombinant bacteria, DNA, RNA, and whole parasite vaccines.
• Enhancement of Immunogen-Elicited Protective Immunity: Status of work on immune enhancers, including adjuvants.
• Manufacturing, Pre-Clinical Development, and Regulatory Approval of Malaria Vaccines: Regulatory and biopharmaceutical sector perspectives.
• Clinical Trials of Malaria Vaccines: Special considerations for design and execution of malaria vaccine trials, including rapid movement from safety studies in adults to safety and efficacy studies in infants, adolescent females, and other important target groups.
  Current status of clinical trials of pre-erythrocytic, asexual erythrocytic, transmission blocking, and multi-stage malaria vaccines.
  Appropriateness of using rates of infection, clinical disease, severe disease, and death as outcome variables.
• Use and Impact of Malaria Vaccines: Modelling the potential impact of malaria vaccines
  The transition from efficacy to effectiveness studies and monitoring impact.
  Tools for monitoring the impact of malaria vaccines.
• Recommendations for the Future

Closing date for poster abstract submissions Friday 27th July 2007

Platinum Sponsor





Sponsored by